- Home
- TRNR vs THAR Comparison
TRNR vs THAR Comparison
Compare TRNR & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNR
- THAR
- Stock Information
- Founded
- TRNR 2017
- THAR 2017
- Country
- TRNR United States
- THAR United States
- Employees
- TRNR N/A
- THAR N/A
- Industry
- TRNR Consumer Electronics/Appliances
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- TRNR Technology
- THAR Health Care
- Exchange
- TRNR Nasdaq
- THAR Nasdaq
- Market Cap
- TRNR 3.9M
- THAR 4.0M
- IPO Year
- TRNR 2023
- THAR 2022
- Fundamental
- Price
- TRNR $1.44
- THAR $1.42
- Analyst Decision
- TRNR
- THAR Strong Buy
- Analyst Count
- TRNR 0
- THAR 1
- Target Price
- TRNR N/A
- THAR $17.00
- AVG Volume (30 Days)
- TRNR 36.3M
- THAR 61.7K
- Earning Date
- TRNR 03-31-2025
- THAR 05-08-2025
- Dividend Yield
- TRNR N/A
- THAR N/A
- EPS Growth
- TRNR N/A
- THAR N/A
- EPS
- TRNR N/A
- THAR N/A
- Revenue
- TRNR $3,180,000.00
- THAR N/A
- Revenue This Year
- TRNR $1,543.45
- THAR N/A
- Revenue Next Year
- TRNR $54.84
- THAR N/A
- P/E Ratio
- TRNR N/A
- THAR N/A
- Revenue Growth
- TRNR 226.82
- THAR N/A
- 52 Week Low
- TRNR $0.86
- THAR $1.28
- 52 Week High
- TRNR $1,640.00
- THAR $7.46
- Technical
- Relative Strength Index (RSI)
- TRNR 44.05
- THAR 33.13
- Support Level
- TRNR $2.13
- THAR $1.28
- Resistance Level
- TRNR $3.96
- THAR $1.65
- Average True Range (ATR)
- TRNR 0.67
- THAR 0.14
- MACD
- TRNR 0.07
- THAR -0.00
- Stochastic Oscillator
- TRNR 21.74
- THAR 23.08
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.